

## The Influence of Some 1-Substituted 6-Methoxy-1,2,3,4-tetrahydro- $\beta$ -carbolines on the Metabolism and Activity of 5-Hydroxytryptamine

RYSZARD J. GRYGLEWSKI, STANISLAW H. MISZTAL, JACEK A. SPLAWINSKI, AND BOGUMILA PANCZENKO

*Department of Pharmacology, Medical Academy and Polish Academy of Sciences, Cracow, Grzegorzewska 16, Poland*


Received January 10, 1966

1-(2-Pyridyl)-, 1-(3-pyridyl)-, and 1-(4-pyridyl)-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carbolines were prepared from 5-methoxytryptamine and the corresponding pyridinealdehydes. These three compounds and six other 1-aryl- and 1-alkyl-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carbolines previously obtained were tested *in vitro* and *in vivo* as antagonists of the biosynthesis and inactivation of 5-hydroxytryptamine (5-HT), and for their interaction with tryptamine receptors. The compounds did not change the activity of 5-hydroxytryptophan decarboxylase (5-HTP-D). Out of nine tested compounds only the 1-(4-pyridyl)-substituted derivative seems to inhibit the activity of monoamine oxidase (MAO). All  $\beta$ -carbolines tested are competitive antagonists of 5-HT, competing for a myotropic tryptamine receptor. In terms of Schild's  $pA_2$  values the most active was the 1-(4-pyridyl)-substituted derivative. Its  $pA_2 = 6.50$  compares with  $pA_2 = 7.52$  of the standard compound (LSD). The least active were the 1-alkyl-substituted derivatives. 1-(4-Pyridyl)-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carboline antagonized tryptamine convulsions in the rat. Unlike LSD none of  $\beta$ -carbolines tested contracted smooth muscles.

The chemical moiety,  $\beta$ -carboline, is common to many biologically active agents.<sup>1</sup> Recently evidence has been found that derivatives of 1,2,3,4-tetrahydro- $\beta$ -carboline are present in the mammalian pineal gland along with 5-hydroxytryptamine (5-HT) and 5-methoxy- $N_\beta$ -acetyltryptamine (melatonin).<sup>2</sup> As a possible physiological role of 1-methyl-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carboline, a substance isolated from pineal tissue, it was proposed that it acted as an aldosterone-releasing factor and the name "adrenoglomerulotropine" was coined.<sup>2a</sup> Newer experiments questioned the influence of this compound on the hormonal activity of adrenal cortex,<sup>3</sup> and so the name "adrenoglomerulotropine" should not be used as the synonym of this particular  $\beta$ -carboline. Nevertheless, 1-methyl-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carboline, as well as 1-benzyl-1,2,3,4-tetrahydro- $\beta$ -carboline and a number of other  $\beta$ -carbolines present in pineal tissue,<sup>2b</sup> certainly plays some physiological role, probably as moderators of 5-HT activity and metabolism.<sup>2c,4</sup> The similar pathway of biogenesis for 5-HT and for pineal  $\beta$ -carbolines makes this assumption even more probable.<sup>2c</sup> Moreover, the influence of plant  $\beta$ -carbolines on 5-HT metabolism seems to be established.<sup>2c,4</sup> The similarity between EEG patterns of cats treated with LSD or with 1-methyl-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carboline<sup>5</sup> may be considered as another proof that pineal  $\beta$ -carbolines are involved in the cerebral metabolism of 5-HT.


The translocation of pyridine nitrogen atom from the  $\beta$  to the  $\gamma$  position in the fused indole-pyridine system of the carboline moiety is an essential factor influencing the biological activity of carbolines.<sup>6</sup> This fact inspired us to synthesize three isomers of 1-pyridyl-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carboline in the hope of

completing a series consisting of 1-methyl-, 1-ethyl-, 1-propyl-, 1-isopropyl-, 1-phenyl-, and 1-benzyl-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carbolines which had been obtained previously.<sup>7</sup> All nine compounds were investigated for their influence on 5-HT metabolism and on 5-HT activity in animal tissues. The three new compounds are: 1-(2-pyridyl)-, 1-(3-pyridyl)-, and 1-(4-pyridyl)-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carbolines (I, II, and III, respectively). Their synthesis was carried out according to general literature methods.<sup>8</sup> Figure 1 shows the infrared absorption spectrum of the isomeric carbolines.



I, R = 2-pyridyl  
II, R = 3-pyridyl  
III, R = 4-pyridyl

The pharmacological investigation was based on the following scheme. We investigated the influence of



$\beta$ -carbolines (1) on the activity of 5-hydroxytryptophan decarboxylase (5-HTP-D) in rat kidneys, (2), on the activity of monoamine oxidase in rat liver, and (3) on the 5-HT interaction with tissue receptors of isolated guinea pig ileum and rat stomach. These *in vitro* experiments were completed by the estimation of the pharmacological activity of  $\beta$ -carbolines in intact cats, rats, and mice.

(1) R. A. Abramovitch and I. D. Spenser, *Advan. Heterocyclic Chem.*, **2**, 79 (1964).

(2) (a) G. Farrell and W. M. McIsaac, *Arch. Biochem. Biophys.*, **94**, 543 (1961); (b) W. M. Isaac, G. Farrell, R. G. Taborsky, and A. N. Taylor, *Science*, **148**, 102 (1965); (c) W. B. Quay, *Pharmacol. Rev.*, **17**, 321 (1965).

(3) G. Farrell in "Aldosterone," E. E. Baulieu and P. Robel, Eds., Blackwell Scientific Publications, Oxford, 1964, p 243; J. Supniewski and R. Rembessa, *Dissertationes Pharm.*, **16**, 131 (1964).

(4) N. J. Giarman and D. X. Freedman, *Pharmacol. Rev.*, **17**, 1 (1965).

(5) J. Trabka, *Dissertationes Pharm.*, **16**, 419 (1964).

(6) P. Nantka-Namirski, S. Kurzepa, J. Duszka, J. Kazimierzcyk, and H. Kierylowicz, *Acta Physiol. Polon.*, **16**, 131 (1965).

(7) J. Supniewski and S. Misztal, *Dissertationes Pharm.*, **16**, 9 (1964).

(8) S. Akabori and K. Saito, *Chem. Ber.*, **63**, 2245 (1930); Z. Pelchowicz and E. D. Bergman, *J. Chem. Soc.*, 4699 (1960); Z. Pelchowicz, A. Kaluszyn, and M. Bentov, *ibid.*, 5418 (1961); M. Protiva, J. O. Jilek, E. Hachova, J. L. Novak, Z. J. Vejdelek, and E. Adlerova, *Chem. Listy*, **51**, 1915 (1957).




Figure 1.—Infrared absorption of the isomeric 1-(pyridyl)-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carbolines.

### Experimental Section<sup>9</sup>

**1-(2-Pyridyl)-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carboline (I).**—5-Methoxytryptamine (1 g), 5.5 ml of 2 *N* H<sub>2</sub>SO<sub>4</sub>, and 0.6 g of pyridine-2-aldehyde were dissolved in 20 ml of water. The solution was stirred and heated in 110° for 30 min, cooled, made alkaline (Na<sub>2</sub>CO<sub>3</sub>), and extracted three times (CHCl<sub>3</sub>). The chloroform layer was washed with water and dried (MgSO<sub>4</sub>). The residue from the chloroform was dissolved in a few milliliters of hot ethanol and slightly acidified with ethanolic HCl. The solution was stored overnight at -5° and yielded 1.15 g of yellow crystals, mp 228–233°. This crude hydrochloride was dissolved in water and made alkaline (Na<sub>2</sub>CO<sub>3</sub>), and the free base was again extracted three times with CHCl<sub>3</sub>. The dry residue from the chloroform layer was dissolved in hot anhydrous benzene and filtered. From this solution crystallized 0.6 g (yield 41.7%) of yellowish product, mp 130–135°. An analytical sample was twice recrystallized from benzene; mp 138–140°.

*Anal.* Calcd for C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O: C, 73.11; H, 6.13; N, 15.04. Found: C, 73.17; H, 6.05; N, 14.81.

**1-(3-Pyridyl)-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carboline (II).**

**A.**—5-Methoxytryptamine (2 g), 7 ml of 2 *N* H<sub>2</sub>SO<sub>4</sub>, and 1.2 g of pyridine-3-aldehyde were dissolved in 40 ml of water, and the solution was stirred and heated in 110° for 30 min. On cooling there crystallized 2 g of crude product. It was filtered, dissolved in hot water, made alkaline (Na<sub>2</sub>CO<sub>3</sub>), and extracted three times with chloroform. The dry residue from the CHCl<sub>3</sub> extract was dissolved in anhydrous chloroform and petroleum ether was added. The product crystallized in a yield of 1.3 g (44.3%), mp 216°. An analytical sample was twice recrystallized from ethanol; mp 219–220°.

**B.**—5-Methoxytryptamine (1 g), 8 ml of 2 *N* HCl, and 0.6 g of pyridine-3-aldehyde were dissolved in 20 ml of water and refluxed 1 hr. The reaction product was treated as in A. The dry residue from the chloroform extract was crystallized from ethanol; 0.6 g of colorless product, mp 210–215° (yield 44.0%).

*Anal.* Calcd for C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O: C, 73.11; H, 6.13; N, 15.04. Found: C, 72.90; H, 6.23; N, 15.00.

**1-(4-Pyridyl)-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carboline (III).**

—5-Methoxytryptamine (2 g), 12 ml of 2 *N* HCl, and 1.2 g of pyridine-4-aldehyde were dissolved in 40 ml of water, refluxed 1 hr, and worked up as in the case of I to give 2.3 g of red crude hydrochloride, mp 221–244°. Finally there was obtained 0.8 g (27.3%) of a canary yellow base, mp 180–184°. An analytical sample was recrystallized many times from benzene; mp 188–192°.

*Anal.* Calcd for C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O: C, 73.11; H, 6.13; N, 15.04. Found: C, 73.39; H, 5.95; N, 14.82.

**Acute Toxicity.**—The compounds were injected intraperitoneally to Porton mice and the acute toxicity was roughly determined. A single dose of a compound was usually injected into three mice. The behavior of animals was observed.

**5-Hydroxytryptamine Biosynthesis.**—Rat kidney homogenates served as the source of 5-HTP-D.<sup>10</sup> The incubation was carried

out in Warburg apparatus. Each vessel contained about 600 mg of tissue homogenized in 2 ml of 0.2 *M* phosphate buffer (pH 8.00) and adjusted to 4 ml with distilled water, 400  $\mu$ g of pyridoxal phosphate, 500  $\mu$ g of iproniazid, and NaCl or a test  $\beta$ -carboline in a final concentration of 0.001 *M*. After 1 hr of incubation at 37° the enzymatic reaction was interrupted by bringing the pH to 5.0 with 0.1 *N* HCl. 5-HT was extracted from the incubation mixture with 20 vol of acetone.<sup>11</sup> The dried extracts were stored at -20° overnight and 5-HT was assayed biologically.<sup>12</sup> The activity of 5-HTP-D was expressed in  $\mu$ g of 5-HT produced by 1 g of kidney within 1 hr of incubation.

**5-Hydroxytryptamine Inactivation.**—Rat liver homogenates served as the source of MAO. The activity of this enzyme was determined manometrically as described previously.<sup>13</sup> However, tryptamine hydrochloride instead of tyramine hydrochloride was used as the substrate.

**Antiserotonin Activity *in Vitro*.**—The investigation was carried out on isolated guinea pig ileum and isolated rat stomach strips<sup>12</sup> bathed in air-bubbled Tyrode solution at 38°. As an agonist of 5-hydroxytryptamine, creatinine sulfate in a concentration of 0.1–10 ng/ml was used. LSD (10–100 ng/ml) and morphine hydrochloride (0.5–2  $\mu$ g/ml) were used as the standard myotropic and neurotropic tryptamine receptor antagonists, respectively.<sup>14</sup> The time of contact with antagonist was 2 min. The antiserotonin activity of  $\beta$ -carbolines was determined using Ariëns' plots<sup>15</sup> and the method of Schild's *p*<sub>17</sub> values.<sup>16</sup> *p*<sub>17</sub> values were determined graphically.<sup>17</sup>

**Antiserotonin Activity *in Vivo*.**—Cats and Wistar rats were anesthetized with chloralose and amobarbital. Blood pressure was recorded from the carotid artery with a Condon manometer. In cats the contractions of the nictitating membrane were registered. All drugs were injected into the femoral vein. Blood pressure response to injection of 5-HT in doses 20–50  $\mu$ g/kg was considered as the standard agonist effect. Antagonists, *i.e.*,  $\beta$ -carbolines, were injected in doses of 1–80 mg/kg 2 min previous to the application of the agonist. The ability of the  $\beta$ -carbolines to antagonize the tryptamine receptor in cerebral tissue was followed by the procedure of Tedeschi and co-workers.<sup>18</sup>

## Results

**Acute Toxicity and Effect on Behavior.**—The LD<sub>50</sub> values were studied between 200 and 500 mg/kg for all compounds. Acute toxicity for the 1-methyl-sub-

(11) A. H. Ajjaj, T. B. Crawford, and J. H. Gaddum, *J. Physiol. (London)*, **126**, 596 (1954).

(12) J. R. Vane, *Brit. J. Pharmacol.*, **12**, 344 (1957).

(13) R. Gryglewski and K. Kubiśka, *Dissertationes Pharm.*, **13**, 111 (1961).

(14) J. H. Gaddum and Z. P. Picavelli, *Brit. J. Pharmacol.*, **12**, 323 (1957).

(15) E. J. Ariëns, A. M. Simonis, and J. M. von Rossum in *Molecular Pharmacology*, E. J. Ariëns, Ed., Academic Press Inc., New York, N. Y., 1964, p 383.

(16) H. O. Schild, *Brit. J. Pharmacol.*, **2**, 189 (1947); **4**, 277 (1949).

(17) R. Gryglewski, S. Wolfarth, and M. Zielinska, *Dissertationes Pharm.*, **17**, 467 (1955).

(18) D. H. Tedeschi, R. E. Tedeschi, and E. J. Fellows, *J. Pharmacol. Exptl. Therap.*, **126**, 223 (1956).

(9) Melting points were determined with Kofler block and are not corrected.

(10) J. H. Gaddum and N. J. Giarman, *Brit. J. Pharmacol.*, **11**, 88 (1956); S. A. P. Price and G. B. West, *J. Pharm. Pharmacol.*, **12**, 617 (1960).

TABLE I  
THE INFLUENCE OF 1-SUBSTITUTED 6-METHOXY-1,2,3,4-TETRAHYDRO- $\beta$ -CARBOLINES ON MAO ACTIVITY  
IN RAT LIVER HOMOGENATES

Radical	Concn. <i>M</i>	% inhib (-) or activation (+) of MAO $\pm$ SE <sup>a</sup>	<i>n</i> <sup>b</sup>	<i>t</i>	<i>P</i>
1-Methyl	0.001	-11.78 $\pm$ 2.25	17	2.153	0.02-0.05
	0.01	-26.63 $\pm$ 1.94	11	5.230	<0.001
1-Ethyl	0.001	+2.68 $\pm$ 1.64	5	0.591	
	0.01	-19.83 $\pm$ 0.72	6	6.177	0.001-0.01
1-Propyl	0.001	+2.63 $\pm$ 2.19	5	0.154	
	0.01	-36.52 $\pm$ 1.43	5	16.907	<0.001
1-Isopropyl	0.001	+8.24 $\pm$ 2.89	6	1.405	
	0.01	-27.18 $\pm$ 2.89	6	7.171	<0.001
1-Phenyl	0.001	-6.45 $\pm$ 2.89	6	1.282	
	0.01		Insoluble		
1-Benzyl	0.001	-16.83 $\pm$ 3.95	16	3.181	0.001-0.01
	0.01		Insoluble		
1-(2-Pyridyl)	0.001	-13.06 $\pm$ 2.65	11	2.622	0.02-0.05
	0.01	-40.46 $\pm$ 3.88	6	10.039	<0.001
1-(3-Pyridyl)	0.001	-1.30 $\pm$ 0.47	6	0.121	
	0.01	-35.67 $\pm$ 2.34	6	9.386	<0.001
1-(4-Pyridyl)	0.001	-16.99 $\pm$ 1.09	12	4.910	<0.001
	0.01	-69.65 $\pm$ 1.41	6	43.505	<0.001
Iproniazid	0.0001	-19.06 $\pm$ 2.95	6	6.100	0.001-0.01
	0.001	-82.64 $\pm$ 1.41	6	—	<0.001

<sup>a</sup> The average MAO activity in *n* = 18 control samples is expressed by the value 119.2  $\pm$  4.7  $\mu$ l of O<sub>2</sub>/1 g of wet tissue per 1 hr.

<sup>b</sup> Number of estimations.

stituted derivative was 350 mg/kg.<sup>19</sup> The difference in toxicity between the particular compounds depends on the chemical nature of the radical at position 1. The toxicity rose successively for 1-alkyl, 1-pyridyl, and 1-aryl derivatives.

With subtoxic doses, a striking difference in the behavior between the animals treated with 1-alkyl and 1-aryl derivatives on the one hand and 1-pyridyl derivatives on the other hand was observed. The first group of  $\beta$ -carbolines produced an excitation followed by atetotic movements and clonic seizures, while the second group was responsible for generalized depression and sleepiness in a nonnarcotic state. Both types of central activity developed 10-20 min after  $\beta$ -carboline injection.

**The Effect on 5-HT Biosynthesis.**—Under our conditions the activity of 5-HTP-D can be expressed as 26.0  $\pm$  2.2  $\mu$ g of 5-HT produced by 1 g of rat kidney within 1 hr for *n* = 9 estimations. Except for 1-ethyl-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carboline, which slightly stimulated the activity of 5-HTP-D, none of the test compounds affected significantly 5-HT biosynthesis. The average activity of 5-HTP-D in the presence of eight  $\beta$ -carbolines studied at 0.001 *M* varied around 104.5  $\pm$  5.4% of 5-HTP-D activity in control homogenates.

**The Effect on 5-HT Inactivation.**—The results are presented in Table I. In control homogenates the activity of MAO was expressed by the value of 119.2  $\pm$  4.7  $\mu$ l of O<sub>2</sub> consumed by 1 g of rat liver within 1 hr for *n* = 18 determinations. All  $\beta$ -carbolines were tested at 0.001 and 0.01 *M* concentrations, while the standard MAO inhibitor, iproniazid, was tested at 0.0001 and 0.001 *M* concentrations. In lower concentrations

only the 1-(4-pyridyl) and 1-benzyl derivatives and iproniazid inhibited the activity of MAO. In higher concentration all soluble compounds inhibited the enzyme. The concentrations employed in this study were rather high, and so  $\beta$ -carbolines are not to be considered as true MAO inhibitors. Only in the case of the 1-(4-pyridyl) and 1-benzyl derivatives was this effect reproducible *in vivo*. Generally speaking the MAO-inhibiting effect of  $\beta$ -carbolines, if any, was obscured *in vivo* by their antiserotonin activity.

**The Effect on 5-HT Receptor *in Vitro*.**—There existed a competitive, reversible antagonism for the myotropic tryptamine receptor between 5-HT and the  $\beta$ -carbolines studied, which could be proved using Ariens' plots.<sup>15</sup> As the pA<sub>2</sub>-pA<sub>10</sub> difference was not significantly smaller than log 9, it could be expected that the antagonism was really competitive and monomolecular.<sup>20</sup> There was no need to use the pK<sub>i</sub> value (the inverse logarithm of the apparent dissociation constant of the complex antagonist-receptors), which should be used in the case of a multimolecular type of antagonism. The  $\beta$ -carbolines did not act on neurotropic tryptamine receptors in guinea pig ileum, since the presence of morphine hydrochloride in Tyrode solution did not change the nature of competition.<sup>14</sup>

The pA<sub>2</sub> values were the real measure for antiserotonin activity of  $\beta$ -carbolines on myotropic receptors in rat stomach strips. LSD was used as the standard myotropic antagonist. The results are presented in Figure 2. The most potent 5-HT antagonists proved to be the 1-(4-pyridyl) and 1-benzyl derivatives, the pA<sub>2</sub> values of which were 6.50 and 6.12, respectively.

(20) M. Rocha e Silva and J. G. Leme in "Recent Advances in the Pharmacology of Toxins," H. W. Raudonath, Ed., Pergamon Press Ltd., London, 1964, p 33.




Figure 2.—The antiserotonin activity of LSD and of nine 1-substituted 6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carbolines expressed as  $pA_2$  values.<sup>16</sup> The compounds were tested on the myotropic tryptamine receptor of rat stomach strips.<sup>12</sup> Each determination was repeated at least three times. The mean deviation of these readings was smaller than 0.15  $pA_2$  unit.

Since the  $pA_2$  value for LSD is 7.52, the most active  $\beta$ -carboline was still only one-tenth as active as the standard antagonist. The least active were 1-alkyl derivatives (see Figure 2).

**The Effect on 5-HT Receptor *in Vivo*.**—Most of investigated  $\beta$ -carbolines reduced markedly the 5-HT effect on blood pressure in the cat and rat, when the compounds were applied in doses 20–30 mg/kg. More active were only the 1-(4-pyridyl) and 1-benzyl derivatives, which when applied at 5–10 mg/kg not only abolished the effect of 5-HT on blood pressure, but also the 5-HT effect on the nictitating membrane in the cat. The antiserotonin effect of the  $\beta$ -carbolines on rat blood pressure lasted much shorter than the antimictitating membrane effect.

The 1-(4-pyridyl) derivative applied intraperitoneally antagonized tryptamine convulsions,  $ED_{50} = 23.5$

(13.1–42.3) mg/kg. Other tryptamine-induced side effects were not antagonized.<sup>18</sup>

### Discussion

The most prominent pharmacological activity of the compounds was on the myotropic tryptamine receptor. All  $\beta$ -carbolines possessed an affinity to the 5-HT receptor but no intrinsic activity when compared with 5-HT. The antiserotonin effect is therefore based on the principles of competitive, monomolecular, and reversible antagonism with 5-HT. The activity of test compounds was confined to values between 4.60 and 6.50  $pA_2$ . Interestingly the most active was the 1-(4-pyridyl) and the least active the 1-(3-pyridyl) derivative (Figure 1). Thus the change of the position of the nitrogen in the pyridine ring attached to the  $\beta$ -carboline moiety can intensify the antiserotonin activity of the compound nearly 100 times. Generally 1-alkyl-substituted derivatives were less active than 1-aryl and 1-pyridyl compounds. In the series of 1-alkyl derivatives longer carbon chain produced stronger antiserotonin properties. The least active was 1-methyl-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carboline previously called "adrenoglomerulotropine." This scale of antiserotonin activity *in vitro* was checked *in vivo* and good agreement was found. All  $\beta$ -carbolines tested were less active than the standard antiserotonin compound. However, LSD in concentrations above 0.1  $\mu\text{g}/\text{ml}$  caused long-lasting contractions of guinea pig ileum, rat stomach, and uterus, while  $\beta$ -carbolines applied even in the high concentration of 100  $\mu\text{g}/\text{ml}$  did not contract smooth muscles. Since this is a very convenient property for an antiserotonin drug, the investigation in the group of  $\beta$ -carbolines could be promising from a practical point of view.

We were not able to find any effect on 5-HT biosynthesis. The slight inhibitory effect of  $\beta$ -carbolines on MAO activity is more pronounced only in the case of the 1-(4-pyridyl) derivative. This enzymatic effect can hardly be demonstrated *in vivo* as the antiserotonin effect of  $\beta$ -carbolines is much stronger.

It should be noted that substitution of 1-alkyl or 1-aryl radicals for one of the 1-pyridyl isomers produced compounds with different central activity. This phenomenon needs further study.